Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer

Lu Wang,Xiao Xiong,Zhimeng Yao,Jianlin Zhu,Yusheng Lin,Wan Lin,Kai Li,Xiaozheng Xu,Yi Guo,Yuping Chen,Yunlong Pan,Fuyou Zhou,Jun Fan,Yan Chen,Shegan Gao,Sai-Ching Jim Yeung,Hao Zhang
DOI: https://doi.org/10.1016/j.canlet.2020.10.052
IF: 9.756
2021-03-01
Cancer Letters
Abstract:<p>Transcription-induced chimeric RNAs are an emerging area of research into molecular signatures for disease biomarker and therapeutic target development. Despite their importance, little is known for chimeric RNAs-relevant roles and the underlying mechanisms for cancer pathogenesis and progression. Here we describe a unique ASTN2-PAPPA<sub>antisense</sub> chimeric RNA (A-P<sub>as</sub>chiRNA) that could be the first reported chimeric RNA derived from the splicing of exons and intron antisense of two neighboring genes, respectively. Aberrant A-P<sub>as</sub>chiRNA level in ESCC tissues was associated with tumor progression and patients' outcome. In vitro and in vivo studies demonstrated that A-P<sub>as</sub>chiRNA aggravated ESCC metastasis and enhanced stemness through modulating OCT4. Mechanistic studies demonstrated that ERK5-mediated non-canonical PAF1 activity was required for A-P<sub>as</sub>chiRNA-induced cancer malignancy. The study defined an undocumented function of chimeric RNAs in aggravating cancer stemness and metastasis.</p>
oncology
What problem does this paper attempt to address?